CPS+EG评分系统在接受新辅助化疗的HER2低表达与HER2零表达早期乳腺癌中的预后分层能力
该回顾性分析纳入608例接受新辅助化疗的HER2非扩增早期乳腺癌患者,按CPS+EG评分分析无病生存和总生存。在ER+肿瘤中,CPS+EG评分在HER2低表达和HER2零表达肿瘤中均似保留预后价值,可区分结局显著不同的群体(好:0-1分,差:2-3分,极差:4-5分)。在ER-肿瘤中,CPS+EG似乎无法区分不同结局组,无论HER2低表达还是HER2零表达;病理分期C指数最高。
要点
- 在ER+早期乳腺癌中,CPS+EG评分在HER2低表达与HER2零表达肿瘤中均似可区分预后组(0-1分、2-3分、4-5分)。
- 在ER-早期乳腺癌中,CPS+EG评分似乎无法区分不同结局组,无论HER2低表达还是HER2零表达。
- HER2低表达状态不影响CPS+EG评分的预后分层能力。
核心结论
- HER2低表达状态不影响CPS+EG评分的预后分层能力。
- 结果证实CPS+EG评分可用于接受新辅助化疗后ER+早期乳腺癌的预后分层,包括HER2零表达和HER2低表达肿瘤。
- 对于ER-早期乳腺癌,HER2低表达状态不影响CPS+EG评分的分层能力,其分层能力低于单独使用病理分期。
研究设计与样本
- 回顾性分析608例接受新辅助化疗的HER2非扩增早期乳腺癌患者,按CPS+EG评分分析无病生存和总生存。
- 分别分析ER+和ER-肿瘤中CPS+EG评分在HER2低表达与HER2零表达早期乳腺癌中的预后分层能力。
主要发现
- 在ER+早期乳腺癌中,CPS+EG评分在HER2低表达和HER2零表达肿瘤中均似保留预后价值,可区分结局显著不同的群体(好:0-1分,差:2-3分,极差:4-5分)。
- 使用无病生存和总生存的C指数,CPS+EG评分在ER+早期乳腺癌中提供最高的预后信息,尤其在HER2零表达肿瘤中。
- 在ER-早期乳腺癌中,CPS+EG评分似乎无法区分不同结局组,无论HER2低表达还是HER2零表达。
- 在ER-早期乳腺癌中,无病生存和总生存的C指数以病理分期最高,反映残留病灶在该亚型中占主导预后重要性。
临床怎么用
- 作者认为,结果支持CPS+EG评分用于接受新辅助化疗后ER+早期乳腺癌的预后分层,包括HER2零表达和HER2低表达肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype. PATIENTS AND METHODS: Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2-0 eBC, analyzing ER+ and ER- tumors separately. RESULTS: In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2-0 tumors, by distinguishing populations with significantly different outcomes (good: score 0-1, poor: score 2-3, and very poor: score 4-5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2-0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2-0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype. CONCLUSIONS: HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2-0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.
引用
- Roussot N, Constantin G, Desmoulins I, et al. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2024. PMID: 38554542. doi:10.1016/j.ejca.2024.114037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。